Brii Biosciences Partners with Joincare Group to Bring Advanced Antibiotic BRII-693 to China

Brii Biosciences Signed a Licensing Agreement with Joincare Group

Image Credits: Vietnam Investment Review

Announcement

Brii Biosciences, a global biotechnology company known for its excellent therapies for various diseases, has signed a technology transfer and license agreement with Joincare Pharmaceutical Group Industry Co., Ltd. Under this exclusive license, Joincare will receive the development, commercialization, and research of BRII-693 in the China region. This agreement will fuel development in Greater China and introduce new technologies to deliver effective therapy to the patients, which will contribute to China’s healthcare market.

Agreement

The terms and conditions of this agreement state that Joincare will undertake responsibility for the regulatory approval, commercialization, and development of BRII-693. This agreement leads to the expansion and introduction of the new antibiotic (treatment) in the China region. Under this agreement, Bio has received development/commercialization and upfront payment, including a contribution to additional events and tiered royalties according to the profit on net product sales.

About BRII-693

BRII-693 is a lipopeptide, an advanced treatment for critically ill patients suffering from multidrug-and extensively drug-resistant (MDR/XDR) gram-negative bacterial infections caused due to Pseudomonas aeruginosa (CRPA), Enterobacterales (CRE), and carbapenem-resistant Acinetobacter baumannii (CRAB). BRII-693 has been developed to improve antibacterial potency by diminishing toxicity that is mainly connected to older polymyxin agents, like neurotoxicities and renal toxicity. After a successful phase 1 study, this new treatment received an IND approval from NMPA and CDE for its PK study in China (phase 1). This will lead to great support for phase 3 (registration trial) for patients suffering from bacterial pneumonia/ventilator, a bacterial pneumonia.

Views and Statements

Chairman and Chief Executive Officer of Brii Bio, Dr. Zhi Hong, said, “The increasing antimicrobial resistance in Greater China requires emergency action for hospital antibiotics. With the support of the Joincare Group’s excellent proven experience in commercializing and manufacturing hospital antibiotics, we have found a valuable partner to elevate our commercialization and development of BRII-693. This collaboration will allow us to provide intricate care medicines to Chinese patients for their respective extreme infections.”

Chief Executive Officer of Joincare Group, Mr. Nanqi Lin, said, “The company has a remarkable record of innovative drug research and development, including a commendable R&D platform and scientific expertise. Brii Bio’s well-developed R&D system has built a strong BRII-693 project that strengthens a scientific and innovative perspective. The current data have shown excellent results in terms of pharmacokinetics, therapeutic potential, and pharmacodynamics that reflect BRII-693's potential. This highlights the readiness to become the best therapy.”